ICD-10-CM Code T80.89XD

Other complications following infusion, transfusion and therapeutic injection, subsequent encounter

Version 2020 Billable Code POA Exempt

Valid for Submission

T80.89XD is a billable code used to specify a medical diagnosis of other complications following infusion, transfusion and therapeutic injection, subsequent encounter. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code T80.89XD might also be used to specify conditions or terms like abdominal hernia as complication of peritoneal dialysis, acute disorder of hemodialysis, acute disorder of hemodialysis, acute disorder of hemodialysis, acute megaloblastic anemia, acute megaloblastic anemia, etc The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

ICD-10:T80.89XD
Short Description:Oth comp fol infusion, transfuse and theraputc inject, subs
Long Description:Other complications following infusion, transfusion and therapeutic injection, subsequent encounter

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Abdominal hernia as complication of peritoneal dialysis
  • Acute disorder of hemodialysis
  • Acute disorder of hemodialysis
  • Acute disorder of hemodialysis
  • Acute megaloblastic anemia
  • Acute megaloblastic anemia
  • Acute megaloblastic anemia due to dialysis
  • Acute megaloblastic anemia secondary to total parenteral nutrition
  • Adynamic bone disease
  • Air in infusion or transfusion due to mechanical failure of apparatus
  • Allergic transfusion reaction
  • Alloimmune platelet transfusion refractoriness
  • Alloimmune thrombocytopenia
  • Anaphylactoid reaction to dialysis
  • Bloodstained peritoneal dialysis effluent
  • Complication of injection
  • Complication of introduction procedure
  • Dialysis dementia
  • Dialysis disequilibrium syndrome
  • Dialysis fluid adverse reaction
  • Dialysis membrane-induced anaphylactoid reaction
  • Dialysis-associated ascites
  • Dialysis-associated hypoxia
  • Encapsulating peritoneal sclerosis associated with peritoneal dialysis
  • Erythema at injection site
  • Erythrocytosis due to autotransfusion
  • Extravasation following blood transfusion
  • Extravasation injury
  • First use syndrome of dialysis
  • Hematoma of dialysis access site
  • Hemodialysis fluid adverse reaction
  • Hemodialysis-associated pruritus
  • Hemodialysis-associated pseudoporphyria
  • Hemofiltration solution adverse reaction
  • Hemolytic transfusion reaction
  • Hemoperitoneum as complication of peritoneal dialysis
  • Hemorrhage into peritoneal cavity
  • Hydrothorax
  • Hydrothorax as complication of peritoneal dialysis
  • Hypercalcemia associated with chronic dialysis
  • Hyperchloremic acidosis associated with dialysis
  • Iatrogenic neonatal hyperglycemia
  • Inadequate hemodialysis
  • Inadequate peritoneal dialysis
  • Induration at injection site
  • Injection neuropathy
  • Injection site anesthesia
  • Injection site atrophy
  • Injection site bruising
  • Injection site burning
  • Injection site cyst
  • Injection site dermatitis
  • Injection site edema
  • Injection site fibrosis
  • Injection site hemorrhage
  • Injection site hypersensitivity
  • Injection site induration
  • Injection site inflammation
  • Injection site irritation
  • Injection site malabsorption
  • Injection site mass
  • Injection site mass
  • Injection site necrosis
  • Injection site nerve damage
  • Injection site pain
  • Injection site paresthesia
  • Injection site pigmentation change
  • Injection site thrombosis
  • Injection site urticaria
  • Injury due to and following infusion
  • Injury due to and following therapeutic injection
  • Injury due to and following transfusion
  • Intestinal obstruction due to a procedure
  • Intravasation of drug or medicament
  • Lipoatrophy
  • Lipoatrophy due to injected drug
  • Lipogranuloma
  • Localized adverse reaction to administration of drug
  • Localized lipoatrophy
  • Long-term disorder of dialysis
  • Loss of solute clearance
  • Loss of ultrafiltration
  • Mechanical failure of instrument or apparatus during infusion or transfusion
  • Mechanical failure of instrument or apparatus during kidney dialysis
  • Megaloblastic anemia due to hemodialysis
  • Megaloblastic anemia due to hyperalimentation
  • Metabolic acidosis, NAG, acidifying salts
  • Neonatal hyperbilirubinemia following total parenteral nutrition
  • Neonatal hyperglycemia
  • Neonatal hyperglycemia due to iatrogenic intravenous therapy
  • Neonatal polycythemia
  • Nontraumatic hemoperitoneum
  • Osteonecrosis due to and following renal dialysis
  • Pain during inflow of dialysate
  • Pain during outflow of dialysate
  • Penile sclerosing lipogranuloma
  • Penile sclerosing lipogranuloma due to injected substance
  • Peritoneal dialysis solution adverse reaction
  • Polycythemia neonatorum following blood transfusion
  • Pseudoporphyria
  • Pulmonary transfusion reaction
  • Sclerosing lipogranuloma
  • Sclerosing peritonitis
  • Sclerosing peritonitis as complication of peritoneal dialysis
  • Skin lesion associated with hemodialysis
  • Skin lesion associated with hemodialysis
  • Swelling at injection site
  • Thrombocytopenia due to extracorporeal circulation of blood
  • Thromboembolism following infusion, perfusion AND/OR transfusion
  • Transfusion hemosiderosis
  • Transfusion reaction due to products of cell metabolism
  • Transfusion reaction due to toxic effect of anticoagulant
  • Transfusion reaction due to toxic substance in blood
  • Ultrafiltration failure
  • Underdialysis
  • Urticarial transfusion reaction

Diagnostic Related Groups

The ICD-10 code T80.89XD is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2019 through 09/30/2020.

  • 949 - AFTERCARE WITH CC/MCC
  • 950 - AFTERCARE WITHOUT CC/MCC

Present on Admission (POA)

T80.89XD is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here .

CMS POA Indicator Options and Definitions
POA Indicator CodePOA Reason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T80.89XD to ICD-9

  • V58.89 - Other specfied aftercare (Approximate Flag)

Code Classification

  • Injury, poisoning and certain other consequences of external causes (S00–T98)
    • Complications of surgical and medical care, not elsewhere classified (T80-T88)
      • Comp following infusion, transfusion and theraputc injection (T80)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020